Safety of Everolimus and Sirolimus-Eluting Coronary Devices in a Patient With Porphyria Presenting With Acute Coronary Syndromes: A Two-Year Follow-Up.

We report the management of a 59-year-old male with genetically confirmed porphyria who underwent two percutaneous coronary interventions (PCI) using Everolimus and Sirolimus-eluting intracoronary devices for acute coronary syndromes. The first PCI involved treatment of mid-LAD disease with a SYNERGY Everolimus-eluting stent. Two years later, the patient re-presented with unstable angina and underwent further PCI using an Xience Everolimus-eluting stent for LAD and a Sirolimus-coated drug-eluting balloon for a CTO in first diagonal branch. Both procedures were successful without any porphyria-related complications. This case highlights the potential safety of Everolimus and Sirolimus-based coronary devices in patients with porphyria.